Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
Yi Ming ang Ke delivers a statement to the main board of the Hong Kong stock exchange to develop a new generation of tumor immunotherapy
China VC Investment List Q4 2022 – Healthcare
For healthcare, we at EqualOcean have identified 20 companies worth watching in Q4 identified by proceedings. We select venture capital investments of over CNY 200 million on average or the equivalent value in USD in a single round.
Jan 05, 2023 06:55 PM
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
F-star to be acquired by China biopharmaceutical with USD 161million
2022 China AI Health 30 Report
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Herui gene launched the early screening product "quansining" for multiple cancer types, covering six high-risk cancer types
East China medicine "liraglutide" goes to sea
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Dynamic Biosystems Snags Nearly CNY 100 Mn in Series A+
Dynamic Biosystems is a single cell and space multi-omics technology platform enterprise. The company focuses on exploring the huge potential in the fields of precision medicine of tumor, eugenics and fertility, and drug discovery, and is committed to promoting precision medicine to the era of single cell and space omics, helping life science and clinical medicine.
Feb 06, 2023 07:25 PM
Opportunities and Challenges Hidden in the CGT Industry in China
CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.
Jan 17, 2023 05:48 PM
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
15 Companies to Watch in December 2022 — Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds and industry events that took place in China's healthcare space in December 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the companies operate.
Jan 04, 2023 05:28 PM
2022 China Year-in-Review | Healthcare
2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the second part, we will list major M&A, product approvals, and strategic collaboration news. It's by no means exhaustive, but it'll shed some light on what's to come
Dec 23, 2022 10:40 AM
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
WaveFront Ventures: How Can Chinese Companies Win the Global Robotic Race
Mar 24, 2023 02:02 PM
CIRCUE: AI Drives the Revolution of Energy, Leading a Sustainable Future
Mar 23, 2023 12:26 PM
Charging Infrastructure on Government Support: A Brighter Future?
Mar 16, 2023 06:03 PM
Robot Policies in Asia
Mar 10, 2023 10:51 AM